Presentation is loading. Please wait.

Presentation is loading. Please wait.

Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist.

Similar presentations


Presentation on theme: "Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist."— Presentation transcript:

1 Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist

2 3 million people have osteoporosis in the UK hip / wrist / vertebra £1.7 billion per annum. Clinical / Public Health Impact

3 Risk of Future Fracture Klotzbuecher, 2000

4 2001 Census

5 Projected Rise in Hip Fractures UK European Commission, 1998

6 Reduction in vertebral fractures Clodronate Alendronate Ibandronate Risedronate Strontium Relative risk ALNCLODIBANRISSR 0.5

7 Risk Factor Case Finding Strategy +

8 Risk Factors Indications for BMD Low trauma # Steroids (oral) > 7.5mg /day – 3 mths Hypogonadism menopause < 45 yrs 2 nd amenorrhoea Radiologic osteopenia Comorbid diseases hyper PTH coeliac disease

9 Medical management of men and women aged 45+ years who have or are at risk of osteoporosis Frail, increased fall risk +/- housebound Risk factorsPrevious fragility fracture Investigations Measure BMD [DXA, hip +/- spine] NORMAL T score above -1 OSTEOPENIA T score –1 to –2.5 OSTEOPOROSIS T score below –2.5 Reassure Lifestyle advice Treat if previous fracture Lifestyle advice Offer treatment* Calcium + Vitamin D Falls risk: Assessment/advice and Consider hip protectors RCP, 1999

10 Limitations Bone Mineral Density Focus on T Score Out of Date

11 Risk Assessment Age Gender Prior Fracture (after age 50 years) Parental history of fracture Current Smoking Alcohol intake > 2 units / day Ever Corticosteroid use Secondary causes (e.g. RA)

12 T Score

13

14

15 NOGG – November 2008 New Risk Assessment Tool ‘FRAX’ - Web Based No More T Scores !– 10 year fracture risk Thresholds for Treatment (web / tables) Advice on which treatment

16 OR

17

18

19

20

21

22 BMD 60yr70yr 80yr No. Risk Factors Women with No Prior #

23

24

25 NOGG - Treatment Alendronate If unable to take / intolerant Risedronate / Ibandronate / Strontium Raloxifene / Etidronate

26 What about NICE? After gestation of 6 years new technology appraisals published late 2008 TA160 : Primary prevention TA 161 : Secondary prevention

27

28 NICE 161– Secondary Prevention Alendronate (ALN) treatment of choice in post-menopausal women if T-score < – 2.5 Unable to take ALN – Risedronate (RIS) or etidronate (ETD) Unable to take RIS /ETD – Strontium / Raloxifene

29

30

31

32 * Age < 65 years + independent clinical risk factor for fracture + clinical risk of low BMD + T-score of < – 2.5 NICE 160– Primary Prevention * Age yrs + independent clinical risk factor for fracture + T-score of < – 2.5

33

34 * Age 75 +yrs + 2 or more risk factors – no need for BMD NICE 160– Primary Prevention * Age 70+ yrs + independent clinical risk factor for fracture OR clinical risk of low BMD + T- score of < – 2.5

35 NICE 160/161 Difficult to use – copy of guidance to hand Restrictive : only few risk factors Unfair ALN first line therapy – Using NOGG many patients will be NICE compliant

36 Summary Osteoporosis is major health problem Effective therapies are available Challenge is targeting treatment – at risk NOGG / FRAX new approach to assessment of risk Use of NOGG should help target treatment to individuals at risk


Download ppt "Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist."

Similar presentations


Ads by Google